Regeneron's Eylea combination therapy fails mid-stage study

(Reuters) – Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *